What the company does
UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases worldwide. The company offers Cimzia for ankylosing spondylitis (AS), axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, polyarticular juvenile idiopathic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; and Neupro for Parkinson's disease and restless legs syndrome. It also provides Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. In addition, the company offers Evenity for the treatment of osteoporosis in postmenopausal women; Bimzelx to treat plaque …
What the weekly tape is saying
UCB closed the latest completed week at 274.9 EUR. The 4-week return is 16.0% and the 12-week return is 12.2%. Trend Signal is active, Market Dynamics is -0.50. Setup signature: Balanced read with a 65/100 composite read.
A compressed read of the whole setup
The radar blends trend persistence, momentum, Market Dynamics, Relative Strength, volume confirmation, and risk control into one weekly cockpit.
Scoreboard
16-week signal tape
Price, Trend Line, and Fair Value
Weekly price context with the latest close, trend position, Fair Value gap, drawdown, and 52-week range location.
52-week price path
Price map
- Trend Line
- 250.2 EUR
- Vs Trend Line
- 9.9%
- Fair Value
- 161.6 EUR
- Vs Fair Value
- 70.1%
- 52W High
- 287.7 EUR
- 52W Low
- 152.7 EUR
- Drawdown
- -4.4%
- Range Position
- 90.5%
Returns and trend persistence
Return windows separate the latest week from short-term and medium-term follow-through.
Return windows
Trend read
- Active Streak
- 1 weeks
- 52W Active Weeks
- 37
- 52W Active Breadth
- 71.2%
- Sector Scope
- BE Healthcare
- Sector Rank
- 2 of 12
- Sector Percentile
- 90.9%
Sector and industry pulse
Peer breadth helps separate a stock-specific move from a broader group rotation.
BE Healthcare
- Tracked Peers
- 12
- 4W Rank
- 3 of 12
- Avg 1W
- -3.8%
- Avg 4W
- -1.8%
- Trend Breadth
- 33.3%
- Positive MD
- 41.7%
BE Biotechnology
- Tracked Peers
- 9
- 4W Rank
- 2 of 9
- Avg 1W
- -1.0%
- Avg 4W
- 0.5%
- Trend Breadth
- 22.2%
- Positive RS
- 33.3%
Pressure, Relative Strength, and expectation
Market Dynamics and Relative Strength show whether buying pressure and relative leadership are confirming the price move.
Dynamics path
Signal state
- Market Dynamics
- -0.50
- 4W MD Change
- 62.8%
- Relative Strength
- 6.19
- 4W RS Change
- 379.3%
- Expectation
- Positive
- Probability
- 59.37%
Participation and confirmation
Volume tells us whether the latest weekly move is being confirmed by unusual participation.
52-week volume profile
Volume map
- Latest Volume
- 865.1K
- 13W Average
- 1.2M
- 52W Average
- 1.2M
- Vs 13W
- 0.7x
- Vs 52W
- 0.8x
Volatility, downside weeks, and return shape
A compact risk profile shows whether the move is steady, volatile, or being driven by sharp one-week jumps.
26-week return distribution
Risk map
- 13W Volatility
- 4.1%
- 52W Volatility
- 5.3%
- Upside Weeks
- 31
- Downside Weeks
- 21
- Downside Breadth
- 40.4%
- Avg Gain / Loss
- 4.0% / -3.0%
Classification, opportunities, risks, and watch points
Top-level read across company classification, constructive evidence, caution points, and the next things that matter.
Classification
- Exchange
- BRU
- Country
- BE
- Sector
- Healthcare
- Industry
- Biotechnology
- Currency
- EUR
- Market Cap
- 48.4B
Opportunity signals
- Trend Signal is active with a 1-week active streak.
- Price is above the Trend Line, keeping the weekly tape constructive.
- Price is above Fair Value, showing premium demand versus the model.
- Latest weekly return ranks in the strongest part of its sector group.
Risk signals
- Market Dynamics is negative, which weakens the current setup.
Watch next
- Price is close to its 52-week high; watch for continuation or exhaustion.
- Trend Line remains the key weekly regime level.
- Market Dynamics is the pressure gauge to monitor for confirmation or fade.
- A volume ratio above 1.5x would show stronger participation in the next move.
Recent completed weeks
The latest weekly rows behind the report snapshot.
| Week | Close | Return | Trend | Fair Value | MD | RS | Volume | Signal |
|---|---|---|---|---|---|---|---|---|
| 12 Jun 2026 | 274.9 EUR | 5.3% | 250.2 EUR | 161.6 EUR | -0.50 | 6.19 | 865.1K | On |
| 5 Jun 2026 | 261.0 EUR | 3.7% | 248.5 EUR | 160.4 EUR | -0.90 | 4.18 | 1.2M | Off |
| 29 May 2026 | 251.7 EUR | 4.0% | 247.4 EUR | 159.3 EUR | -1.19 | 0.88 | 1.6M | Off |
| 22 May 2026 | 242.0 EUR | 2.1% | 246.3 EUR | 158.2 EUR | -1.36 | -2.71 | 1.1M | Off |
| 15 May 2026 | 237.0 EUR | 1.2% | 246.3 EUR | 157.1 EUR | -1.34 | -2.22 | 864.7K | Off |
| 8 May 2026 | 234.1 EUR | 1.9% | 246.7 EUR | 156.2 EUR | -1.05 | -3.01 | 1.1M | Off |
| 1 May 2026 | 229.8 EUR | -3.3% | 247.3 EUR | 155.2 EUR | -0.68 | -2.51 | 1.5M | Off |
| 24 Apr 2026 | 237.5 EUR | -9.4% | 248.0 EUR | 154.2 EUR | -0.46 | 1.21 | 1.4M | On |
| 17 Apr 2026 | 262.2 EUR | -4.0% | 246.6 EUR | 153.3 EUR | -0.31 | 7.62 | 1.5M | On |
| 10 Apr 2026 | 273.3 EUR | 4.0% | 244.6 EUR | 152.1 EUR | -0.39 | 15.30 | 1.1M | On |
| 3 Apr 2026 | 262.8 EUR | 5.0% | 242.4 EUR | 150.9 EUR | -0.58 | 16.89 | 834.8K | On |
| 27 Mar 2026 | 250.4 EUR | 2.2% | 240.5 EUR | 149.7 EUR | -0.52 | 17.27 | 1.4M | On |
| 20 Mar 2026 | 245.1 EUR | -1.2% | 238.8 EUR | 148.6 EUR | -0.30 | 17.07 | 1.6M | On |
| 13 Mar 2026 | 248.0 EUR | -0.6% | 237.1 EUR | 147.6 EUR | 0.13 | 14.57 | 1.2M | On |